v3.26.3
Contingent Consideration (Details)
€ in Thousands
12 Months Ended
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2026
EUR (€)
Jun. 30, 2025
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2022
EUR (€)
Contingent Consideration [Line Items]            
Cash paid $ 750,000          
AVb6 Integrin intellectual property [member]            
Contingent Consideration [Line Items]            
Payment of license agreement         $ 10,000,000  
Payment for development milestone   $ 90,000,000        
Payments for milestones        
AVb6 Integrin intellectual property [member] | Top of range [member]            
Contingent Consideration [Line Items]            
Payments for milestones 12,500,000          
AVb6 Integrin intellectual property [member] | Bottom of range [member]            
Contingent Consideration [Line Items]            
Payments for milestones $ 11,750,000          
hu PSA Anti-body intellectual property [member]            
Contingent Consideration [Line Items]            
Payment for development milestone   1      
Payment of license agreement         7,000,000  
Payment for development milestone   123,500,000        
NanoMab intellectual property [member]            
Contingent Consideration [Line Items]            
Payments for milestones   3   3    
Payment of license agreement         $ 12,500,000  
Payment for development milestone   18,000,000        
Pharma15 [Member]            
Contingent Consideration [Line Items]            
Payments for milestones        
Payment of license agreement   2,000,000        
Payment for development milestone   2,300,000        
Pivalate intellectual property [member]            
Contingent Consideration [Line Items]            
Payments for milestones        
Payment of license agreement (in Euro) | €           € 180,000,000
Payment for development milestone (in Euro) | €     € 35,780      
Radiopharm Ventures LLC [Member]            
Contingent Consideration [Line Items]            
Payments for milestones   1      
Payment for development milestone   72,280,000        
First patient dosed in the first Phase 1 therapeutic clinical trial [member] | NanoMab intellectual property [member]            
Contingent Consideration [Line Items]            
Payments for milestones   2        
Deferred Payment [Member] | Pharma15 [Member]            
Contingent Consideration [Line Items]            
Payment of license agreement   $ 2,000,000